Results 251 to 260 of about 333,660 (389)

Comparison of ultracentrifugation and polyethylene glycol precipitation for concentration of hepatitis B virus (HBV) DNA for molecular hybridisation tests and the relationship of HBV-DNA to HBe antigen and anti-HBe status

, 1991
Debasish Sanyal, Goura Kudesia, Gerald Corbitt   +2 more
openalex   +1 more source

Hepatitis in Used Syringes: The Limits of Sensitivity of Techniques to Detect Hepatitis B Virus (HBV) DNA, Hepatitis C Virus (HCV) RNA, and Antibodies to HBV Core and HCV Antigens [PDF]

, 1996
Robert Heimer, Kaveh Khoshnood, B Jariwala-Freeman, Brynn B. Duncan, Yoshikazu Harima   +4 more
openalex   +1 more source

Prediction of Hepatocellular Carcinoma and Other Liver‐Related Events in Chronic Hepatitis B Patients With Metabolic Dysfunction or Metabolic Dysfunction‐Associated Steatotic Liver Disease

Alimentary Pharmacology &Therapeutics, EarlyView.
This study evaluated the performance of the PAGE‐B score in HCC risk among CHB patients with metabolic dysfunction or MASLD. The PAGE‐B score effectively stratified HCC risk in both MASLD and non‐MASLD patients, especially in those without cirrhosis, where low scores were linked to negligible 5‐year HCC risk. ABSTRACT Introduction Metabolic dysfunction
Lesley A. Patmore, Ivana Carey, Jordan J. Feld, Willem P. Brouwer, Keyur Patel, Maria Buti, Pieter Honkoop, Douwe F. Postma, Hans Blokzijl, Özgur. M. Koc, Eva van Oorschot, Kosh Agarwal, Marc van der Valk, Faydra I. Lieveld, Mai Kilany, Matthijs Kramer, Joep de Bruijne, Mark A. A. Claassen, Bettina E. Hansen, Robert A. de Man, Harry L. A. Janssen, R. Bart Takkenberg, Milan J. Sonneveld   +22 more
wiley   +1 more source

Combined Analysis of Protein Induced by Prothrombin Induced by Vitamin K Absence (PIVKA) and Alpha-L-Fucosidase (AFU) with Alpha-Fetoprotein (AFP) May Improve the Diagnostic Efficacy for Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis B. [PDF]

Int J Gen Med
Hou H, Weng R, Liang L, Han W.
europepmc   +1 more source

Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer

Alimentary Pharmacology &Therapeutics, EarlyView.
In a cohort of 1596 liver cancer patients with either current or prior HBV infection undergoing systemic therapy in Hong Kong, the risk of HBV reactivation during immune checkpoint inhibitor treatment was low when adequate antiviral prophylaxis was administered, irrespective of HBV infection status.
Dorothy Cheuk‐Yan Yiu, Jimmy Che‐To Lai, Landon Long Chan, Grace Lai‐Hung Wong, Mandy Sze‐Man Lai, Vincent Wai‐Sun Wong, Yee‐Kit Tse, Henry Lik‐Yuen Chan, Stephen Lam Chan, Terry Cheuk‐Fung Yip   +9 more
wiley   +1 more source

The epidemiology of hepatitis b virus infection in Uganda after two decades of vaccination: a meta-analysis and meta-regression. [PDF]

BMC Infect Dis
Kafeero HM, Sendagire H, Ndagire D, Walusansa A, Kudamba A, Muwanda F, Namusoke M, Ocama P.   +7 more
europepmc   +1 more source

Heterogeneous HBV mutants coexist in Korean hepatitis B patients [PDF]

, 1998
Won Kyoung Keum, J. Y. Kim, Jayoung Kim, Sung Gil, Junseok Hong, Sung-Soo Kim, Joohun Ha, Insug Kang   +7 more
openalex   +1 more source

Is HBV RNA a new endpoint of HBV cure?

Saudi Journal of Gastroenterology
openaire   +3 more sources

Non‐Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis

Alimentary Pharmacology &Therapeutics, EarlyView.
In a multi‐centre study of obeticholic acid in primary biliary cholangitis, 45% discontinued the drug over 4 years, with 11% moving to combination therapy (fibrates). Of those continuing, response rates increased from 37% (1 year) to 55% (4 years). Non‐response at 12 months and cirrhosis were independent predictors of liver‐related events.
Nadir Abbas, Rachel Smith, Ellina Lytvyak, Miki Scaravaglio, Neil Halliday, Amal Almahroos, Nadia Eden, Diane Lloyd‐Madden, Sanchit Sharma, James Ferguson, Jessica K. Dyson, Douglas Thorburn, David Jones, Aldo J. Montano‐Loza, Marco Carbone, Pietro Invernizzi, George Mells, Emma L. Culver, Palak J. Trivedi   +18 more
wiley   +1 more source

Intermittent loss of anti-HBc antibodies in people with multiple sclerosis undergoing disease-modifying therapies. [PDF]

BMC Infect Dis
Pasculli P, Ngangue YCF, Zingaropoli MA, Dominelli F, Ciccone F, Antonacci M, Ferrazzano G, Campagna R, Turriziani O, Antonelli G, Mastroianni CM, Conte A, Ciardi MR.   +12 more
europepmc   +1 more source